These human in vitro models of hepatic steatosis highlight how DPYD enzymatic activity significantly contributes to lipid homeostasis and demonstrate how pharmacologic inhibition of DPYD may be a potential treatment option for the mitigation of diet-induced microvesicular steatosis. The gene discussed is DPYD; the disease is Hepatic steatosis.